Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate dissociates into calcium ions that raise extracellular calcium concentration. The increased calcium enhances neuromuscular transmission, improves myocardial contractility, and participates in bone mineralisation, thereby restoring normal physiological functions that depend on calcium.

The dose of Icalziss is determined by the prescribing clinician based on the patient’s serum calcium level, clinical condition, and the specific therapeutic context. Healthcare professionals calculate the appropriate amount and rate of infusion for each individual case.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Icalziss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Icalziss provides calcium in a highly soluble, injectable form suitable for extracorporeal administration, whereas oral calcium salts such as calcium carbonate are used for chronic supplementation. The injectable route allows rapid correction of severe hypocalcaemia and precise dosing during procedures like dialysis.

Icalziss should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture and direct sunlight. Do not freeze the solution, and ensure the vial is kept upright to avoid leakage.

Icalziss is administered intravenously via an extracorporeal circuit or a dedicated IV line. The infusion rate and total volume are set by the treating clinician, who monitors the patient’s vital signs and serum calcium levels throughout the procedure.

The most serious risks include severe hypercalcaemia, which can cause cardiac arrhythmias or arrest, and tissue necrosis if the solution extravasates from the vein. Prompt recognition and immediate medical intervention are essential if these events occur.

Icalziss should be avoided in patients with known hypersensitivity to calcium chloride, uncontrolled hypercalcaemia, or severe cardiac conduction disorders unless closely monitored. Clinicians must evaluate each patient’s medical history before initiating therapy.